[S05] Frontiers in Mid-Size Drug Research -Diverse Approaches to Mid-size Drug Development-

Sun. Mar 26, 2023 10:10 AM - 12:10 PM [Room M1] The Alumni Hall "Frate": Hall (1F)

Organizer: Akira Shigenaga, Kohei Tsuji

Recently, development of mid-size drugs such as peptides and nucleotides becomes a new attractive modality because these drugs can possess advantages of both small molecular drugs and biopharmaceuticals. Since the first approval of the peptide hormone drug in 1960s, more than 60 kinds of peptide-based drugs have been approved and clinically used in Japan. In addition, since the first oligonucleotide therapeutics, Vitravene, was approved by FDA in 1998, a number of oligonucleotide therapeutics have been developed and their market size is expanding year by year.
The mid-size drugs contain a lot of molecules including peptides, oligonucleotides, glycans, lipids, and chimeric molecules. Therefore, researchers in various fields are actively conducting a wide variety of mid-side drug discovery researches. In this symposium “Frontiers in Mid-size Drug Research – Diverse Approaches to Mid-size Drug Development –,” six researchers in different fields will present the state of the art topics; “chimeric molecules for target protein degradation (Itoh),” “mitigation of off-target effects of antisense oligonucleotides (T. Yamamoto),” “cancer immunotherapy utilizing glycoconjugates (Manabe),” “drug discovery based on lysophospholipids (K. Yamamoto),” “exploration of drug seeds using mirror-image natural products and biomolecules (Oishi)” and “anti-SARS-CoV-2 peptides learned from HIV research (Tsuji).”

+Add all to schedule

オーガナイザー挨拶：重永章（福山大薬） (10:10 AM - 10:15 AM)

10:15 AM - 10:35 AM

[S05-01] Drug discovery research on chimeric molecules

○Yukihiro Itoh¹ (1. SANKEN, Osaka Univ.)

10:35 AM - 10:55 AM

[S05-02] Mitigation of off-target interactions of antisense oligonucleotide

○Tsuyoshi Yamamoto¹ (1. Nagasaki Univ.)

10:55 AM - 11:10 AM

[S05-03] Development of cancer immunotherapy using glycoconjugate middle molecules

○Yoshiyuki Manabe^1,2 (1. Grad. Sch. Sci., Osaka Univ., 2. FRC, Osaka Univ.)

11:10 AM - 11:30 AM

[S05-04] Drug discovery based on lysophospholipids

○Kei Yamamoto¹ (1. Div. Biosci. Bioindustry, Tokushima Univ.)

11:30 AM - 11:50 AM

[S05-05] Access to a vast virtual library of mirror-image natural products and biomolecules

○Shinya Oishi¹ (1. Kyoto Pharm. Univ.)

11:50 AM - 12:05 PM

[S05-06] Development of SARS-CoV-2 fusion inhibitor peptides learned from HIV-1 study

○Kohei Tsuji¹ (1. IBB, TMDU)

総括：辻耕平（医科歯科大生体材料工学研） (12:05 PM - 12:10 PM)